The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Biosimilars Drug Market Research Report 2025

Global Biosimilars Drug Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1791144

No of Pages : 110

Ask Your Query
Synopsis
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
Global Biosimilars Drug market is projected to reach US$ 15220 million in 2029, increasing from US$ 2830 million in 2022, with the CAGR of 25.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Biosimilars Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Biosimilars Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Qilu Pharmaceutical
Bio-Thera
Zhejiang Hisun
Shanghai Henlius
Innovent Biologics
Jiangsu Hengrui
Gan&Lee
Tonghua Dongbao
United Laboratory
3SBIO
Luye Pharma
Celltrion
Pfizer
Novartis
Dr Reddy’s
Celgen Biopharma
Eli Lilly
Sanofi
Geropharm
Biocon
Wockhardt
Segment by Type
Monoclonal Antibodies
Insulin
Others
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Biosimilars Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biosimilars Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Monoclonal Antibodies
1.2.3 Insulin
1.2.4 Others
1.3 Market by Application
1.3.1 Global Biosimilars Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biosimilars Drug Market Perspective (2018-2029)
2.2 Biosimilars Drug Growth Trends by Region
2.2.1 Global Biosimilars Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Biosimilars Drug Historic Market Size by Region (2018-2023)
2.2.3 Biosimilars Drug Forecasted Market Size by Region (2024-2029)
2.3 Biosimilars Drug Market Dynamics
2.3.1 Biosimilars Drug Industry Trends
2.3.2 Biosimilars Drug Market Drivers
2.3.3 Biosimilars Drug Market Challenges
2.3.4 Biosimilars Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biosimilars Drug Players by Revenue
3.1.1 Global Top Biosimilars Drug Players by Revenue (2018-2023)
3.1.2 Global Biosimilars Drug Revenue Market Share by Players (2018-2023)
3.2 Global Biosimilars Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Biosimilars Drug Revenue
3.4 Global Biosimilars Drug Market Concentration Ratio
3.4.1 Global Biosimilars Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosimilars Drug Revenue in 2022
3.5 Biosimilars Drug Key Players Head office and Area Served
3.6 Key Players Biosimilars Drug Product Solution and Service
3.7 Date of Enter into Biosimilars Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Biosimilars Drug Breakdown Data by Type
4.1 Global Biosimilars Drug Historic Market Size by Type (2018-2023)
4.2 Global Biosimilars Drug Forecasted Market Size by Type (2024-2029)
5 Biosimilars Drug Breakdown Data by Application
5.1 Global Biosimilars Drug Historic Market Size by Application (2018-2023)
5.2 Global Biosimilars Drug Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Biosimilars Drug Market Size (2018-2029)
6.2 North America Biosimilars Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Biosimilars Drug Market Size by Country (2018-2023)
6.4 North America Biosimilars Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biosimilars Drug Market Size (2018-2029)
7.2 Europe Biosimilars Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Biosimilars Drug Market Size by Country (2018-2023)
7.4 Europe Biosimilars Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biosimilars Drug Market Size (2018-2029)
8.2 Asia-Pacific Biosimilars Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Biosimilars Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Biosimilars Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biosimilars Drug Market Size (2018-2029)
9.2 Latin America Biosimilars Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Biosimilars Drug Market Size by Country (2018-2023)
9.4 Latin America Biosimilars Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biosimilars Drug Market Size (2018-2029)
10.2 Middle East & Africa Biosimilars Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Biosimilars Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Biosimilars Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Qilu Pharmaceutical
11.1.1 Qilu Pharmaceutical Company Detail
11.1.2 Qilu Pharmaceutical Business Overview
11.1.3 Qilu Pharmaceutical Biosimilars Drug Introduction
11.1.4 Qilu Pharmaceutical Revenue in Biosimilars Drug Business (2018-2023)
11.1.5 Qilu Pharmaceutical Recent Development
11.2 Bio-Thera
11.2.1 Bio-Thera Company Detail
11.2.2 Bio-Thera Business Overview
11.2.3 Bio-Thera Biosimilars Drug Introduction
11.2.4 Bio-Thera Revenue in Biosimilars Drug Business (2018-2023)
11.2.5 Bio-Thera Recent Development
11.3 Zhejiang Hisun
11.3.1 Zhejiang Hisun Company Detail
11.3.2 Zhejiang Hisun Business Overview
11.3.3 Zhejiang Hisun Biosimilars Drug Introduction
11.3.4 Zhejiang Hisun Revenue in Biosimilars Drug Business (2018-2023)
11.3.5 Zhejiang Hisun Recent Development
11.4 Shanghai Henlius
11.4.1 Shanghai Henlius Company Detail
11.4.2 Shanghai Henlius Business Overview
11.4.3 Shanghai Henlius Biosimilars Drug Introduction
11.4.4 Shanghai Henlius Revenue in Biosimilars Drug Business (2018-2023)
11.4.5 Shanghai Henlius Recent Development
11.5 Innovent Biologics
11.5.1 Innovent Biologics Company Detail
11.5.2 Innovent Biologics Business Overview
11.5.3 Innovent Biologics Biosimilars Drug Introduction
11.5.4 Innovent Biologics Revenue in Biosimilars Drug Business (2018-2023)
11.5.5 Innovent Biologics Recent Development
11.6 Jiangsu Hengrui
11.6.1 Jiangsu Hengrui Company Detail
11.6.2 Jiangsu Hengrui Business Overview
11.6.3 Jiangsu Hengrui Biosimilars Drug Introduction
11.6.4 Jiangsu Hengrui Revenue in Biosimilars Drug Business (2018-2023)
11.6.5 Jiangsu Hengrui Recent Development
11.7 Gan&Lee
11.7.1 Gan&Lee Company Detail
11.7.2 Gan&Lee Business Overview
11.7.3 Gan&Lee Biosimilars Drug Introduction
11.7.4 Gan&Lee Revenue in Biosimilars Drug Business (2018-2023)
11.7.5 Gan&Lee Recent Development
11.8 Tonghua Dongbao
11.8.1 Tonghua Dongbao Company Detail
11.8.2 Tonghua Dongbao Business Overview
11.8.3 Tonghua Dongbao Biosimilars Drug Introduction
11.8.4 Tonghua Dongbao Revenue in Biosimilars Drug Business (2018-2023)
11.8.5 Tonghua Dongbao Recent Development
11.9 United Laboratory
11.9.1 United Laboratory Company Detail
11.9.2 United Laboratory Business Overview
11.9.3 United Laboratory Biosimilars Drug Introduction
11.9.4 United Laboratory Revenue in Biosimilars Drug Business (2018-2023)
11.9.5 United Laboratory Recent Development
11.10 3SBIO
11.10.1 3SBIO Company Detail
11.10.2 3SBIO Business Overview
11.10.3 3SBIO Biosimilars Drug Introduction
11.10.4 3SBIO Revenue in Biosimilars Drug Business (2018-2023)
11.10.5 3SBIO Recent Development
11.11 Luye Pharma
11.11.1 Luye Pharma Company Detail
11.11.2 Luye Pharma Business Overview
11.11.3 Luye Pharma Biosimilars Drug Introduction
11.11.4 Luye Pharma Revenue in Biosimilars Drug Business (2018-2023)
11.11.5 Luye Pharma Recent Development
11.12 Celltrion
11.12.1 Celltrion Company Detail
11.12.2 Celltrion Business Overview
11.12.3 Celltrion Biosimilars Drug Introduction
11.12.4 Celltrion Revenue in Biosimilars Drug Business (2018-2023)
11.12.5 Celltrion Recent Development
11.13 Pfizer
11.13.1 Pfizer Company Detail
11.13.2 Pfizer Business Overview
11.13.3 Pfizer Biosimilars Drug Introduction
11.13.4 Pfizer Revenue in Biosimilars Drug Business (2018-2023)
11.13.5 Pfizer Recent Development
11.14 Novartis
11.14.1 Novartis Company Detail
11.14.2 Novartis Business Overview
11.14.3 Novartis Biosimilars Drug Introduction
11.14.4 Novartis Revenue in Biosimilars Drug Business (2018-2023)
11.14.5 Novartis Recent Development
11.15 Dr Reddy’s
11.15.1 Dr Reddy’s Company Detail
11.15.2 Dr Reddy’s Business Overview
11.15.3 Dr Reddy’s Biosimilars Drug Introduction
11.15.4 Dr Reddy’s Revenue in Biosimilars Drug Business (2018-2023)
11.15.5 Dr Reddy’s Recent Development
11.16 Celgen Biopharma
11.16.1 Celgen Biopharma Company Detail
11.16.2 Celgen Biopharma Business Overview
11.16.3 Celgen Biopharma Biosimilars Drug Introduction
11.16.4 Celgen Biopharma Revenue in Biosimilars Drug Business (2018-2023)
11.16.5 Celgen Biopharma Recent Development
11.17 Eli Lilly
11.17.1 Eli Lilly Company Detail
11.17.2 Eli Lilly Business Overview
11.17.3 Eli Lilly Biosimilars Drug Introduction
11.17.4 Eli Lilly Revenue in Biosimilars Drug Business (2018-2023)
11.17.5 Eli Lilly Recent Development
11.18 Sanofi
11.18.1 Sanofi Company Detail
11.18.2 Sanofi Business Overview
11.18.3 Sanofi Biosimilars Drug Introduction
11.18.4 Sanofi Revenue in Biosimilars Drug Business (2018-2023)
11.18.5 Sanofi Recent Development
11.19 Geropharm
11.19.1 Geropharm Company Detail
11.19.2 Geropharm Business Overview
11.19.3 Geropharm Biosimilars Drug Introduction
11.19.4 Geropharm Revenue in Biosimilars Drug Business (2018-2023)
11.19.5 Geropharm Recent Development
11.20 Biocon
11.20.1 Biocon Company Detail
11.20.2 Biocon Business Overview
11.20.3 Biocon Biosimilars Drug Introduction
11.20.4 Biocon Revenue in Biosimilars Drug Business (2018-2023)
11.20.5 Biocon Recent Development
11.21 Wockhardt
11.21.1 Wockhardt Company Detail
11.21.2 Wockhardt Business Overview
11.21.3 Wockhardt Biosimilars Drug Introduction
11.21.4 Wockhardt Revenue in Biosimilars Drug Business (2018-2023)
11.21.5 Wockhardt Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock